Payment overview · 2025
General Payments
$1,899.03
130 reported records · 18 companies
Healthcare provider profile · identity verified
Christopher William Orendorff, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SALLISAW, OK · NPI 1922233618
Verified facts
What the public records show
CMS Open Payments records show Christopher William Orendorff, M.D. received $1,899.03 in general payments during 2025 across 130 reported records.
Novo Nordisk Inc accounted for 13.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Gemtesa, Jardiance, Kerendia, Mounjaro, Nurtec Odt, Ozempic, Rexulti, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 252 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 295 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 226 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 237 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 295 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Nurtec Odt by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $258.09 | 13.6% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $254.76 | 13.4% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $223.19 | 11.8% | 21 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $176.48 | 9.3% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $174.84 | 9.2% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $146.70 | 7.7% | 19 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $143.77 | 7.6% | 9 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $103.31 | 5.4% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $74.94 | 4.0% | 5 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $65.72 | 3.5% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54.95 | 2.9% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $53.32 | 2.8% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.20 | 2.4% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $41.37 | 2.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $27.30 | 1.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $23.51 | 1.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.38 | 0.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.20 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,899.03 | 130 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $238.77 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $193.26 | 19 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $176.48 | 12 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $174.84 | 12 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $138.06 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $122.97 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $120.03 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $107.63 | 17 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $103.31 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $97.70 | 14 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $94.86 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $75.75 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $74.94 | 5 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $65.72 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $53.32 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $46.20 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $41.37 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.93 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $27.30 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.24 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $23.51 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 11 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 295 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 167 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 143 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 160 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 237 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 226 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
252 | 51 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | 17 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
143 | 39 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
295 | 63 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
226 | 57 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
143 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
160 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
237 | 62 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
295 | 63 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
167 | 28 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1221 | 344 |
| Gabapentin | Gabapentin | 935 | 197 |
| Amlodipine Besylate | Amlodipine Besylate | 882 | 245 |
| Lisinopril | Lisinopril | 763 | 231 |
| Levothyroxine Sodium | Levothyroxine Sodium | 713 | 176 |
| Pantoprazole Sodium | Pantoprazole Sodium | 583 | 161 |
| Omeprazole | Omeprazole | 568 | 162 |
| Potassium Chloride | Potassium Chloride | 492 | 135 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 490 | 148 |
| Furosemide | Furosemide | 477 | 129 |
| Meloxicam | Meloxicam | 423 | 128 |
| Tamsulosin Hcl | Tamsulosin Hcl | 416 | 109 |
| Metformin Hcl | Metformin Hcl | 385 | 104 |
| Carvedilol | Carvedilol | 376 | 109 |
| Trazodone Hcl | Trazodone Hcl | 376 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 363 | 116 |
| Losartan Potassium | Losartan Potassium | 351 | 101 |
| Sertraline Hcl | Sertraline Hcl | 333 | 94 |
| Metoprolol Tartrate | Metoprolol Tartrate | 315 | 97 |
| Eliquis | Apixaban | 295 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 283 | 76 |
| Clopidogrel | Clopidogrel Bisulfate | 274 | 75 |
| Tizanidine Hcl | Tizanidine Hcl | 270 | 75 |
| Duloxetine Hcl | Duloxetine Hcl | 254 | 59 |
| Farxiga | Dapagliflozin Propanediol | 252 | 51 |
| Buspirone Hcl | Buspirone Hcl | 250 | 61 |
| Ozempic | Semaglutide | 237 | 62 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 226 | 57 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 203 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 189 | 39 |
| Montelukast Sodium | Montelukast Sodium | 187 | 52 |
| Simvastatin | Simvastatin | 172 | 43 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 168 | 41 |
| Gemtesa | Vibegron | 167 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 164 | 57 |
| Mounjaro | Tirzepatide | 160 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 156 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 153 | 44 |
| Allopurinol | Allopurinol | 147 | 37 |
| Jardiance | Empagliflozin | 143 | 39 |
| Xarelto | Rivaroxaban | 142 | 34 |
| Famotidine | Famotidine | 141 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 141 | 45 |
| Ondansetron Odt | Ondansetron | 140 | 49 |
| Citalopram Hbr | Citalopram Hydrobromide | 139 | 42 |
| Ropinirole Hcl | Ropinirole Hcl | 130 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 124 | 39 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 120 | 28 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 117 | 30 |
| Pregabalin | Pregabalin | 109 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 106 | 26 |
| Ventolin Hfa | Albuterol Sulfate | 106 | 30 |
| Azithromycin | Azithromycin | 105 | 92 |
| Torsemide | Torsemide | 105 | 39 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 103 | 32 |
| Mirtazapine | Mirtazapine | 97 | 21 |
| Ibuprofen | Ibuprofen | 96 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 94 | 27 |
| Tramadol Hcl | Tramadol Hcl | 92 | 36 |
| Memantine Hcl | Memantine Hcl | 91 | 20 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 88 | 23 |
| Alprazolam | Alprazolam | 85 | 19 |
| Lovastatin | Lovastatin | 85 | 25 |
| Metformin Hcl Er | Metformin Hcl | 85 | 34 |
| Warfarin Sodium | Warfarin Sodium | 85 | 18 |
| Bupropion Xl | Bupropion Hcl | 84 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 84 | 73 |
| Prednisone | Prednisone | 79 | 51 |
| Entresto | Sacubitril/Valsartan | 78 | 22 |
| Spironolactone | Spironolactone | 78 | 24 |
| Nitroglycerin | Nitroglycerin | 76 | 34 |
| Alendronate Sodium | Alendronate Sodium | 75 | 19 |
| Donepezil Hcl | Donepezil Hcl | 75 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 72 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 72 | 20 |
| Finasteride | Finasteride | 71 | 15 |
| Cefdinir | Cefdinir | 69 | 59 |
| Januvia | Sitagliptin Phosphate | 69 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 19 |
| Glimepiride | Glimepiride | 68 | 21 |
| Levetiracetam | Levetiracetam | 68 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 67 | 65 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 15 |
| Promethazine Hcl | Promethazine Hcl | 65 | 14 |
| Ezetimibe | Ezetimibe | 64 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 23 |
| Glipizide | Glipizide | 60 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 60 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 58 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 29 |
| Breo Ellipta | Fluticasone/Vilanterol | 56 | 16 |
| Nystatin | Nystatin | 56 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 17 |
| Clonidine Hcl | Clonidine Hcl | 54 | 15 |
| Baclofen | Baclofen | 52 | 11 |
| Topiramate | Topiramate | 52 | 12 |
| Aripiprazole | Aripiprazole | 51 | 12 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 51 | 16 |
| Celecoxib | Celecoxib | 50 | 22 |
| Colestipol Hcl | Colestipol Hcl | 50 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 19 |
| Myrbetriq | Mirabegron | 50 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | suppressed |
| Estradiol | Estradiol | 48 | 16 |
| Glipizide Er | Glipizide | 48 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 23 |
| Ranolazine Er | Ranolazine | 48 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 47 | 11 |
| Trulicity | Dulaglutide | 47 | 14 |
| Synthroid | Levothyroxine Sodium | 46 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 15 |
| Atenolol | Atenolol | 44 | 18 |
| Kerendia | Finerenone | 44 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Cephalexin | Cephalexin | 43 | 31 |
| Fluconazole | Fluconazole | 42 | 32 |
| Methocarbamol | Methocarbamol | 41 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 11 |
| Divalproex Sodium | Divalproex Sodium | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 15 |
| Primidone | Primidone | 40 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 39 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 39 | suppressed |
| Vraylar | Cariprazine Hcl | 39 | suppressed |
| Linzess | Linaclotide | 38 | suppressed |
| Methylprednisolone | Methylprednisolone | 38 | 35 |
| Ketoconazole | Ketoconazole | 37 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 37 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | 17 |
| Mupirocin | Mupirocin | 35 | 29 |
| Nebivolol Hcl | Nebivolol Hcl | 35 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Acyclovir | Acyclovir | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | 11 |
| Lorazepam | Lorazepam | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 27 |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | 12 |
| Trintellix | Vortioxetine Hydrobromide | 24 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | 16 |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | 11 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Roflumilast | Roflumilast | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | 12 |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,899.03 · 130 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, CAPLYTA, COBENFY, Cologuard Collection Kit, ELIQUIS, FANAPT, GEMTESA, GLASSIA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error